Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: The FILLY, OAKS and DERBY trials have demonstrated that local inhibition of C3 cleavage with pegcetacoplan can reduce geographic atrophy lesion growth compared with sham with an effect size of approximately 11-35% depending on the specific trial and specific geographic atrophy phenotype considered. Overall pegcetacoplan has appeared to be well tolerated with the notable side effect of a dose-dependent increase in the rate of exudative AMD development in treated eyes. SUMMARY: The FILLY, OAKS and DERBY trials have demonstrated that pegcetacoplan is a potentially viable treatment for geographic atrophy. Additional data from the 2-year outcomes of DERBY and OAKS as well as data from the ongoing 3-year GALE extension study will provide additional insights into the potential therapeutic benefit of pegcetacoplan. Future studies assessing complement inhibition at earlier stages of AMD, with the goal of preventing geographic atrophy formation, are warranted.
|
Authors | Sagar B Patel, Jeffrey S Heier, Varun Chaudhary, Charles C Wykoff |
Journal | Current opinion in ophthalmology
(Curr Opin Ophthalmol)
(Oct 11 2023)
ISSN: 1531-7021 [Electronic] United States |
PMID | 37815317
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. |